Hypericin diagnostic - Sanochemia
Alternative Names: Polyvinylpyrrolidone-hypericin; Povidone-hypericin; PVP-hypericin; SPH-3542; VidonLatest Information Update: 27 Feb 2023
At a glance
- Originator Planta Natural Products
- Developer Austrian Academy of Sciences; Sanochemia Pharmazeutika
- Class Anthraquinones; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsoriatics; Antivirals; Cytostatics; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Skin disorder therapies; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bladder cancer
Most Recent Events
- 24 Feb 2023 Discontinued - Preclinical for Bladder cancer in Austria (Intravesicular) (Sanochemia Diagnostics pipeline, February 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Bladder-cancer in Austria (Intravesicular, Injection)
- 31 Jan 2018 PVP-hypericin is still in preclinical development for Bladder cancer in Austria (Sanochemia Pharmazeutika pipeline, January 2018)